C
Constance M. Yuan
Researcher at National Institutes of Health
Publications - 133
Citations - 10629
Constance M. Yuan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Minimal residual disease & Multiple myeloma. The author has an hindex of 35, co-authored 133 publications receiving 8169 citations.
Papers
More filters
Journal ArticleDOI
Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain
Lekha Mikkilineni,Elisabet E. Manasanch,Danielle Vanasse,Jennifer N. Brudno,Jennifer Mann,Richard M. Sherry,Stephanie L. Goff,James Chih-Hsin Yang,Norris Lam,Irina Maric,Maryalice Stetler-Stevenson,Hao-Wei Wang,Constance M. Yuan,David F. Stroncek,Steven L. Highfill,Vicki Fellowes,Micaela Ganadan,Rashmika Patel,Steven A. Rosenberg,James N. Kochenderfer +19 more
TL;DR: A novel, fully-human, heavy-chain-only anti-BCMA binding domain designated FHVH33 is used to reduce the risk of recipient immune responses against CAR T cells, which resulted in objective responses (OR) in 20 patients and two patients came off study due to progressive MM.
Journal ArticleDOI
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.
Elisabet E. Manasanch,Raul C. Braylan,Maryalice Stetler-Stevenson,Constance M. Yuan,Verena Gounden,Neha Korde,Nishant Tageja,Manisha Bhutani,Katherine R. Calvo,Irina Maric,Mark Roschewski,Louis M. Staudt,Ola Landgren +12 more
TL;DR: In this article, the prevalence and clinical significance of the MYD88 L265P somatic mutation in 58 cases of immunoglobulin M (IgM) secreting lymphoplasmacytic lymphoma (LPL)/Wal...
Journal ArticleDOI
Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities
Neha Korde,Sham Mailankody,Mark Roschewski,Malek Faham,Chitra Kotwaliwale,Martin Moorhead,Mary L Kwok,Elisabet E. Manasanch,Manisha Bhutani,Nishant Tageja,Dickran Kazandjian,Rene Costello,Yong Zhang,Adriana Zingone,Debbie Burton,Marcia Mulquin,Ashley Carpenter,Diamond Zuchlinski,Elizabeth Lamping,George Carter,Candis Morrison,Karen A. Kurdziel,Maria Liza Lindenberg,Roger Kurlander,Irina Maric,Katherine R. Calvo,Raul C. Braylan,Constance M. Yuan,Maryalice Stetler-Stevenson,Diane C. Arthur,Seth M. Steinberg,William D. Figg,Peter L. Choyke,Ola Landgren +33 more
TL;DR: The comprehensive assessment of MRD in a uniformly treated cohort of 45 MM patients, using universal primer sets, found that among pts assessed by both MRD methods, 23 samples were concordant (9 pos and 14 neg); among 8 discordant cases, all were positive by sequencing and negative by flow.
Journal ArticleDOI
Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection
Wenbin Xiao,Dalia Salem,Catharine S. McCoy,Daniel Lee,Nirali N. Shah,Maryalice Stetler-Stevenson,Constance M. Yuan +6 more
TL;DR: CD19‐targeted chimeric‐antigen receptor‐modified T‐cells (CAR‐T) are promising in the treatment of refractory B‐lymphoblastic leukemia (B‐ALL) and minimal residual disease detection by multicolor flow cytometry (FCM) is critical to distinguish B‐ALL MRD from regenerating, non‐neoplastic B‐cell populations.
Journal ArticleDOI
Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
Nishant Tageja,Neha Korde,Dickran Kazandjian,Sandhya R. Panch,Elisabet E. Manasanch,Manisha Bhutani,Mary Kwok,Sham Mailankody,Constance M. Yuan,Maryalice Stetler-Stevenson,Susan F. Leitman,Claude Sportes,Ola Landgren +12 more
TL;DR: Observations support 6 cycles of KRd as an efficacious and safe induction strategy prior to stem-cell collection for newly diagnosed multiple myeloma patients.